Department of Ophtalmology, Henan Eye Hospital, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People's Republic of China.
Department of Ophthalmology, Guangdong Eye Institute, Guangdong Provincial People' s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China.
Drug Des Devel Ther. 2022 Mar 15;16:717-725. doi: 10.2147/DDDT.S351683. eCollection 2022.
This study aimed to assess the short-term changes of macular microstructures following anti-VEGF and anti-inflammatory therapies in patients with macular edema secondary to retinal vein occlusion (RVO-ME).
In this retrospective study, 70 eyes of 70 patients with RVO-ME were divided into the anti-VEGF (Group A, 35 eyes) and anti-inflammatory (Group B, 35 eyes) treatment groups. All patients underwent best-corrected visual acuity (BCVA) assessment, intraocular pressure (IOP) assessment, slit lamp, fundus fluorescein angiography (FA), scanning laser ophthalmoscopy (SLO), and spectral-domain optical coherence tomography (SD-OCT). Group A received intravitreal injection of 0.05 mL anti-VEGF antibodies (Lucentis or Aflibercept) monthly for 3 consecutive months, while Group B received 0.7 mg dexamethasone (Ozurdex) single intravitreal injection. BCVA and SD-OCT biomarkers were recorded at baseline and 3 months after the first injection. Changes of BCVA and SD-OCT biomarkers following these treatments were compared between the two groups.
BCVA and SD-OCT biomarkers, except choroidal thickness, in both groups were significantly improved after treatment (all < 0.01). At 3 months, the height of serous retinal detachment (SRD) was markedly lower ( = 0.006), with significantly less hyperreflective dots (HRD, = 0.037) in Group B compared with Group A. Other SD-OCT biomarkers and BCVA were not significantly different between the two groups (all > 0.05).
Anti-VEGF and anti-inflammatory therapies are both effective in RVO-ME, with improvement in BCVA and SD-OCT biomarkers. Anti-inflammatory therapy may be more effective than anti-VEGF therapy in SRD and HRD resolution.
本研究旨在评估抗血管内皮生长因子（VEGF）和抗炎治疗对视网膜静脉阻塞（RVO）继发黄斑水肿（RVO-ME）患者黄斑微观结构的短期变化。
在这项回顾性研究中，70 例 RVO-ME 患者的 70 只眼分为抗 VEGF 治疗组（A 组，35 只眼）和抗炎治疗组（B 组，35 只眼）。所有患者均进行最佳矫正视力（BCVA）评估、眼压（IOP）评估、裂隙灯检查、眼底荧光素血管造影（FA）、扫描激光检眼镜（SLO）和频域光学相干断层扫描（SD-OCT）。A 组患者每月接受 0.05ml 抗 VEGF 抗体（Lucentis 或 Aflibercept）玻璃体腔内注射，连续 3 个月；B 组患者接受 0.7mg 地塞米松（Ozurdex）单次玻璃体腔内注射。在基线和首次注射后 3 个月记录 BCVA 和 SD-OCT 生物标志物。比较两组患者治疗后 BCVA 和 SD-OCT 生物标志物的变化。
两组患者的 BCVA 和 SD-OCT 生物标志物（脉络膜厚度除外）在治疗后均显著改善（均<0.01）。治疗 3 个月后，B 组患者的浆液性视网膜脱离（SRD）高度明显降低（=0.006），高反射点（HRD）明显减少（=0.037）。与 A 组相比，两组间其他 SD-OCT 生物标志物和 BCVA 差异均无统计学意义（均>0.05）。
抗 VEGF 和抗炎治疗对 RVO-ME 均有效，均可改善 BCVA 和 SD-OCT 生物标志物。与抗 VEGF 治疗相比，抗炎治疗可能更有利于 SRD 和 HRD 的消退。
